Leung, 2002 - Google Patents
Management of viral hepatitis CLeung, 2002
- Document ID
- 14844340762689382408
- Author
- Leung N
- Publication year
- Publication venue
- Journal of Gastroenterology and Hepatology
External Links
Snippet
The hepatitis C virus was first identified in 1989. It causes chronic hepatitis, cirrhosis and hepatocellular carcinoma. Global anti‐HCV prevalence is 1–3%. Contaminated blood product, dirty needles and instruments, and injection drug use are the main parenteral …
- 208000005176 Hepatitis C 0 title abstract description 44
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2292—Thymosin; Related peptides
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Leung | Management of viral hepatitis C | |
| Yu et al. | Treatment of chronic hepatitis C in Asia: when East meets West. | |
| Yu et al. | 2020 Taiwan consensus statement on the management of hepatitis C: Part (II) special populations | |
| Alpers et al. | KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease: introduction | |
| Yoshimi et al. | Long term persistence of NS5A inhibitor‐resistant hepatitis C virus in patients who failed daclatasvir and asunaprevir therapy | |
| Aman et al. | Current status and future directions in the management of chronic hepatitis C | |
| Chen et al. | Antiviral treatment to prevent chronic hepatitis B or C-related hepatocellular carcinoma | |
| Chuang et al. | Treatment of chronic hepatitis C in southern Taiwan | |
| Kew et al. | Prevention of hepatitis C virus infection | |
| Wedemeyer | Hepatitis D revival | |
| Hsu et al. | Hepatitis C virus infection, antiviral therapy, and risk of hepatocellular carcinoma | |
| Forestier et al. | Triple therapy with telaprevir: results in hepatitis C virus‐genotype 1 infected relapsers and non‐responders | |
| Akuta et al. | Favorable efficacy of glecaprevir plus pibrentasvir as salvage therapy for HCV failures to prior direct‐acting antivirals regimens | |
| Huang et al. | Comparison of naturally occurring resistance-associated substitutions between 2008 and 2016 in Chinese patients with chronic hepatitis C virus infection | |
| Bourlière et al. | Optimal therapy of genotype‐2 chronic hepatitis C: what's new? | |
| Kiyosawa et al. | GB virus C/hepatitis G virus | |
| Sano et al. | Role of NS5A-L31/Y93 double wild-type in failure of glecaprevir/pibrentasvir double therapy in two patients with a history of direct-acting antiviral agent failure: an ultra-deep sequencing analysis | |
| Nasser et al. | Recent trends in chronic hepatitis C virus treatment | |
| Cheng et al. | Racial differences in responses to interferon‐β‐1a in chronic hepatitis C unresponsive to interferon‐α: a better response in Chinese patients | |
| Nagra et al. | Therapeutic Advances in Viral Hepatitis A–E | |
| Stevens et al. | Hepatitis C virus: an important occupational hazard? | |
| Bresci et al. | Interferon plus ribavirin in chronic hepatitis C non‐responders to recombinant α‐interferon | |
| Nonomura et al. | Sofosbuvir/Velpatasvir Plus Ribavirin Combination Therapy for Patients with Hepatitis C Virus Genotype 1a, 2a, or 3b after Glecaprevir/Pibrentasvir Therapy Failed | |
| Bacon et al. | Triple therapy with boceprevir for HCV genotype 1 infection: phase III results in relapsers and nonresponders | |
| Aboushady et al. | Retreatment of Egyptian chronic hepatitis C patients not responding to pegylated interferon and ribavirin dual therapy |